

REVIEW

Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury

Philipp Kruger¹, Mona Saffarzadeh², Alexander N. R. Weber³, Nikolaus Rieber⁴, Markus Radsak⁵, Horst von Bernuth^{6,7}, Charaf Benarafa⁸, Dirk Roos⁹, Julia Skokowa¹⁰, Dominik Hartl^{4*}

1 Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom, **2** Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany, **3** Institute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany, **4** Department of Pediatrics I, University of Tübingen, Tübingen, Germany, **5** 3rd Dept. of Medicine, Johannes Gutenberg-University Medical Center, Mainz, Germany, **6** Department of Pediatric Pneumology and Immunology, Charité Hospital, Humboldt University, Berlin, Germany, **7** Fachbereich Immunologie, Labor Berlin Charité Vivantes GmbH, Berlin, Germany, **8** Theodor Kocher Institute, University of Bern, Bern, Switzerland, **9** Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands, **10** Department of Internal Medicine II, University of Tübingen, Tübingen, Germany

* dominik.hartl@med.uni-tuebingen.de



 OPEN ACCESS

Citation: Kruger P, Saffarzadeh M, Weber ANR, Rieber N, Radsak M, von Bernuth H, et al. (2015) Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury. *PLoS Pathog* 11(3): e1004651. doi:10.1371/journal.ppat.1004651

Editor: Christoph Dehio, University of Basel, SWITZERLAND

Published: March 12, 2015

Copyright: © 2015 Kruger et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the German Research Foundation (DFG, Emmy Noether Programme HA 5274/3-1 to DH) and the CRC/SFB685 at Tübingen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

Neutrophils, the most abundant human immune cells, are rapidly recruited to sites of infection, where they fulfill their life-saving antimicrobial functions. While traditionally regarded as short-lived phagocytes, recent findings on long-term survival, neutrophil extracellular trap (NET) formation, heterogeneity and plasticity, suppressive functions, and tissue injury have expanded our understanding of their diverse role in infection and inflammation. This review summarises our current understanding of neutrophils in host-pathogen interactions and disease involvement, illustrating the versatility and plasticity of the neutrophil, moving between host defence, immune modulation, and tissue damage.

Neutrophil's Life Cycle Granulopoiesis

Neutrophils are the predominant immune cell population in human blood, where they patrol and protect us from pathogens, and diseases with neutropenia show that they are indispensable for controlling bacterial and fungal infections. Neutrophils develop in the bone marrow from haematopoietic stem cells in a process called “granulopoiesis” and mature neutrophils are characterised by their segmented nucleus and granules that are filled with >700 proteins [1]. Bone marrow neutrophil lineage cells can be divided into three compartments: (i) the stem cell pool composed of hematopoietic stem cells and pluripotent progenitors; (ii) the mitotic pool composed of proliferating, lineage-committed myeloblasts, promyelocytes, and myelocytes; and (iii) the post-mitotic pool composed of metamyelocytes, band cells, and mature neutrophils.

Post-mitotic bone marrow neutrophils constitute 95% of the neutrophils in the body [2,3] and this reserve is easily mobilized and recruited rapidly to sites of infection.

Granulocyte colony-stimulating factor (G-CSF) is the predominant factor regulating the neutrophil's life cycle by increasing cell proliferation, survival, differentiation, and trafficking/mobilization. Mice lacking G-CSF or its receptor have a profound, but not absolute, neutropenia in bone marrow and blood [2,4,5]. However, these mice can still produce mature neutrophils in steady state and increase their production and mobilization in “emergency” situations, indicating that other signals can provide partial or complete compensation [6]. Moreover, G-CSF induces proliferation and expression of anti-apoptotic proteins and regulates chemokine expression [7,8]. However, the precise mechanisms by which G-CSF signals regulate mitotic and post-mitotic neutrophils are not fully understood. Maintenance of neutrophil numbers is further regulated by phagocytosis of apoptotic neutrophils by macrophages, a process termed “efferocytosis.” Efferocytosis reduces the production of interleukin (IL)-23 and IL-17 and dampens G-CSF production [9]. G-CSF thus regulates the neutrophil life cycle at multiple levels and, consequently, has become an important therapeutic agent for neutropenic diseases, as discussed below. Recently, autophagy has been reported as a negative regulator of neutrophil development in the bone marrow [10].

Mobilization and trafficking

Chemokines orchestrate the balance between neutrophil release and retention. Bone marrow stromal cells produce C-X-C-motif chemokine ligand (CXCL) 12 that binds to C-X-C-motif chemokine receptor (CXCR) 4, leading to neutrophil retention, while release is mainly mediated by CXCR2 [11]. Pharmacologic CXCR2 inhibition in healthy humans, using ozone- or LPS-induced inflammation models [12–15], or in patients with severe asthma [16] or cystic fibrosis (CF) [17] showed that CXCR2 inhibition is safe and decreases neutrophilic inflammation in the airways.

Clearance of apoptotic neutrophils by macrophages, a mechanism involving liver X receptor (LXR), is essential for immune homeostasis and impaired clearance of apoptotic neutrophils has been linked to autoimmune disease [18–20]. Recent murine studies have extended this concept by highlighting the role of the bone marrow as a site of neutrophil clearance [21]. Intriguingly, homing of senescent neutrophils back to the bone marrow was found to regulate the circadian release of hematopoietic progenitors into the circulation [22]. However, the relevance of this circadian mechanism for neutrophil homeostasis in humans remains debatable. Another layer of complexity has been added by the concept of reverse neutrophil migration from peripheral organs back into the bloodstream. Reverse transmigration has been first observed in endothelial cells *in vitro* [23], and in mice *in vivo* [24], and has then been defined as a novel mechanism of inflammation resolution in zebrafish models [25]. Despite these fascinating mechanistic insights, their relevance for human diseases remains to be defined.

Released neutrophils are proposed to disseminate in the periphery into circulating and marginated neutrophil pools. The latter refers to neutrophils adherent to endothelial cells in the spleen, liver, bone-marrow, and the lung that can be recovered by exercise and adrenaline [26]. While a recent study highlights the importance of the pulmonary marginated pool in mice [27], its role in humans, at least under homeostatic conditions, remains questionable since the injection of non-primed autologous neutrophils did not lead to a significant retention in the pulmonary vasculature [28]. Further studies are required to shed more light on the marginated neutrophil pool in man and mice.

The traditional paradigm of neutrophils as short-lived immune cells has been challenged by *in vivo*-labelling studies, demonstrating a life span of 5.4 days for human neutrophils [29], ten

times longer than previously estimated, and suggesting that neutrophils shape immune responses beyond rapid host–pathogen interactions. However, alternative explanations have been proposed [30,31] and there is no broad consensus yet regarding the life span of neutrophils in humans. Furthermore, *in vivo*-labelling studies are required to solve these controversies and to gain deeper insight into the neutrophil’s life span, particularly under infectious disease conditions.

Neutrophil serine proteases, serpins, and neutrophil survival

Amongst the broad armamentarium that neutrophils carry in their granules, neutrophil serine proteases directly kill microbes and inactivate bacterial toxins [32,33]. Excessive host tissue damage and inflammation driven by the uncontrolled activity of these proteases (namely elastase, proteinase-3, and cathepsin G) is counterbalanced by endogenous serine protease inhibitors (“serpins”) [34]. Besides protecting the body from free and harmful proteolytic activities, recent studies demonstrate that serpins have an unexpectedly broader role in regulating neutrophil survival. This novel function was first hinted at by mice lacking the intracellular inhibitor Serpinb1a, which showed reduced neutrophil survival and severe bone marrow neutropenia [35], rendering these mice susceptible to bacterial and viral lung infections [36,37]. Further studies showed that Serpinb1a is critical for maintaining neutrophil survival by blocking cell-intrinsic death mediated by cathepsin G and proteinase-3 [38,39].

Neutrophil–Pathogen Interactions

Recent findings have substantially expanded our view on the repertoire of antimicrobial effector functions of the neutrophil in host–pathogen interactions. Beyond phagocytosis, neutrophils employ neutrophil extracellular traps (NETs) [40] to capture microbes extracellularly and autophagy to digest them intracellularly [41,42]. Several factors decide which antibacterial effector functions are activated: (i) the presence of serum favors phagocytosis but inhibits the formation of NETs [43], (ii) transmigration triggers the release of contents from secretory vesicles and specific granules, and (iii) cell adherence lowers the threshold for integrin-dependent neutrophil activation. Importantly, intravital microscopy imaging approaches have expanded our understanding of neutrophil–pathogen interactions extensively. A recent study using this technology showed that phagocytosis and NETosis act in concert to combat *Staphylococcus aureus* *in vivo*, supporting a novel “neutrophil multitasking” concept in host–pathogen interactions [44]. Other *in vivo* studies demonstrated intracapillary neutrophil crawling in *S. aureus* infection [45] and dynamic and intravascular NET formation in bacterial [46] and viral infections [47]. Fig. 1 illustrates the diversity of neutrophil effector mechanisms in host–pathogen interactions.

In the paragraphs below, the key neutrophil effector functions are discussed.

Phagocytosis

Neutrophils are rapid and potent phagocytes. Upon ligation of opsonic receptors, such as Fcγ receptors, C-type lectins or complement receptors, the neutrophil membrane engulfs a particle or a microbe, a process that is mediated by a complex interplay of membrane lipids, intracellular signalling cascades, and cytoskeletal rearrangements. Subsequently, primary and secondary granules fuse with the phagosome and discharge their antimicrobial contents. Phagocytosis occurs within minutes and is enhanced by the complement system, IgG antibodies, and cell pre-activation. Once specific granules fuse with the phagosome, the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is assembled from the membrane-bound flavocytochrome *b*₅₅₈, consisting of p91^{phox} (phagocyte oxidase) and p22^{phox} subunits, and the cytoplasmic components p47^{phox}, p67^{phox}, p40^{phox}, and Rac. Potassium ion (K⁺) fluxes also occur




Fig 1. Neutrophil effector mechanisms. The mechanisms neutrophils employ to fight infections include phagocytosis, the release of various granule components into the extracellular space or into the phagosome (mainly proteases, oxidants, antimicrobial peptides), and the formation of neutrophil extracellular traps (NETs).

doi:10.1371/journal.ppat.1004651.g001

in response to NADPH oxidase activation [48]. Reeves et al. hypothesised that K^+ , in turn, releases granule proteases that mediate bacterial killing, suggesting that the NADPH oxidase reaction mainly serves as an activator for proteases instead of being a microbicidal mechanism itself [49], a concept that has been challenged [50], most recently by a study showing that serine protease deficient human neutrophils show no impairment in killing bacteria [51]. The killing of *S. aureus* can be restored in NADPH oxidase-deficient neutrophils by adding liposomes loaded with glucose oxidase [52] or polyethylene glycol-conjugated D-amino acid oxidase [53], which produces H_2O_2 . In these systems, neutrophils were still able to kill bacteria even when the NADPH oxidase was inactive. Moreover, inhibition of the NADPH oxidase does not impair killing of *S. pneumoniae* [54], and NADPH oxidase-deficient neutrophils from chronic granulomatous disease (CGD, see below) patients are still able to kill *Escherichia coli*, indicating

additional microbicidal mechanisms independent of reactive oxygen species (ROS) production. A recent study further shows the involvement of the nucleotide-binding oligomerisation domain (NOD)-like receptor family, pyrin domain-containing protein (NLRP) 3 inflammasome in macrophage phagocytosis by demonstrating that activation of caspase-1 controls the phagosomal pH by regulating the NADPH oxidase (NOX) 2 to control phagosome function in gram-positive, but not gram-negative infections [55].

Neutrophil Extracellular Traps (NETs)

NET induction. The concept of NETosis was introduced in 2004 [40] as a novel mechanism for neutrophils to release extracellular DNA traps, composed of decondensed chromatin, histones, and granule proteins. This finding inspired a variety of studies employing different NETosis-inducing agents, including bacteria, fungi, protozoa, viruses, platelets, nitric oxide donors, and others. NET formation has been described as a novel form of cell death [56], involving the translocation of elastase from primary granules to the nucleus, where it cleaves specific histones and leads to chromatin decondensation [57]. Other studies support the notion that even viable neutrophils can form NETs, consisting of mitochondrial [58] or nuclear DNA, in a rapid and non-lytic manner [44]. Neutrophils treated with NADPH oxidase inhibitors or cells from CGD patients show impaired NET formation in response to phorbol-12-myristate-13-acetate (PMA) or *S. aureus* [56], and CGD gene therapy restored NET formation [59], suggesting that ROS are indispensable for NET formation. However, other studies suggested that ROS involvement depends on the stimulus [60–63]. In addition to ROS, several other pathways have been reported to be involved in NET formation, such as peptidyl arginine deiminase (PAD) 4 [64], the Raf-MEK (mitogen-activated kinase/ERK kinase)-ERK (extracellular signal-regulated kinase) pathway [65] and autophagy [66].

Microbial NETosis escape mechanisms. Pathogens have evolved a variety of mechanisms to escape from host defence. One of these mechanisms is the expression of DNase to degrade NETs. *Streptococcal* DNases render the bacteria resistant to NET-mediated killing [67–69]. Similar results have been obtained with other pathogens. However, the killing capacity of NETs was questioned by a study showing that pathogens entrapped in NETs survived and retained their ability to proliferate after being released from NETs [70], an issue requiring further investigations.

NETs in pathological conditions. Although NET generation has been described initially as an antimicrobial mechanism, recent data suggest that NETs could play a more important role in autoimmune and autoinflammatory pathologies, such as vasculitis [71], lung injury [72,73], atherosclerosis [74], rheumatoid arthritis [75,76], thrombosis [77–80], gout [81], and systemic lupus erythematosus (SLE) [43,82]. Several strategies have been proposed to interfere with NETs, particularly digestion of NET-DNA with DNase or targeting NET-associated proteins. DNase is successfully used to treat patients with CF, and its beneficial effect may be due to cleaving NETs [83,84]. Other approaches were so far mainly restricted to animal models and require clinical studies to assess their therapeutic usefulness.

Several aspects of NET formation remain enigmatic [85]. Despite a large number of studies demonstrating NET formation in vitro, our understanding of NET formation in vivo is limited. Most studies used PMA to induce NETs, while the major driver(s) of NET formation under (patho)physiological conditions remain poorly understood. A recent study suggests that particularly larger pathogens, such as fungal hyphae, induce NET formation [86]. Another open question is why some neutrophils form NETs and others do not. This heterogeneity remains enigmatic, but recent studies indicate that NET formation could be linked to olfactomedin 4 expression by a subset of neutrophils [87]. Moreover, the biological relevance of lytic/cell

death-associated versus non-lytic/viable NET formation remains an open question [88]. While viable and rapid NET formation has been established in mice, human studies are scarce, but propose a role for this rapid NET formation mechanism in *S. aureus* infections [60]. Neutrophils have a relatively low content of mitochondrial DNA compared to nuclear DNA. Nevertheless, mitochondrial DNA is released following physiological stimuli and may represent a distinct form of NET formation [58]. While there is evidence for an involvement of elastase, PAD-4, and histone citrullination in NET formation, the precise cellular machinery leading to NET release is incompletely defined. For example, how elastase escapes from primary granules to reach the nucleus and what physical forces lead to propulsion of nucleic acids outside the cells remain largely elusive. How important are NETs in comparison to other neutrophil effector functions with regards to bacterial killing? A recent study in Papillon-Lefèvre syndrome, where neutrophils lack active serine proteases, such as elastase, showed that patient's neutrophils failed to form NETs, but were fully competent to kill bacteria [51]. These data indicate that serine proteases are essential for NET formation, but that NET formation, in turn, could be dispensable for killing of certain bacteria. Further studies with more bacterial, fungal, and viral pathogens are required to solve these issues.

Antimicrobial peptides

Antimicrobial peptides play a major role at epithelial barriers and are secreted into various body fluids, such as sweat, alveolar lining fluid, milk, or intestinal mucus [89]. Most peptides in human neutrophil granules, like bactericidal/permeability-increasing protein, α -defensins, and cathelicidins, execute their microbicidal effects by disrupting bacterial membranes. Lactoferrin and lipocalin inhibit microbial iron uptake, and lysozyme cleaves cell wall peptidoglycans. Beyond their antimicrobial activities, cathelicidins (or their processed cleavage product LL-37) and α -defensins can also act as proinflammatory mediators and chemokine receptor agonists. Antimicrobial peptides, released by neutrophils, are also associated to NETs [85], facilitating a close interaction with NET-entangled pathogens.

Neutrophils and the Microbiome

The gut microbiome has attracted high interest in various fields of research and there is now compelling evidence to support the notion that mucosal commensals regulate granulopoiesis and neutrophil homeostasis at several levels. Prolonged antibiotic treatment leads to reduced neutrophil numbers and germ-free animals present a severe neutropenia, indicating a close and homeostatic link between microbiota and neutrophils [90–92]. While our understanding of cellular and molecular mechanisms remains incomplete, the regulation of neutrophil homeostasis by the microbiome seems to be mediated by structural features of bacteria that can activate innate pattern recognition receptors, leading to increased neutrophil production [93–95]. There is also emerging evidence that metabolites, such as short chain fatty acids, produced by gut commensals from dietary fibers, regulate neutrophil-mediated inflammation through the chemoattractant receptor G protein-coupled receptor (GPR) 43 expressed at high levels by neutrophils [96]. Dysbiosis (that is, altered microbiome composition) has been associated with increased incidence and severity of various chronic inflammatory diseases and cancer [97,98], yet the interaction between microbiota and neutrophils in these conditions remains to be established. Moreover, further studies are warranted to determine whether an altered microbiome induces changes in neutrophil phenotypes and functions and, vice versa, whether targeting neutrophils has an effect on the microbiome.

Neutrophil–Immune Cell Interactions

Neutrophils can interact with a variety of immune and non-immune cells at several levels, best studied for dendritic cells (DCs), macrophages, natural killer (NK) cells, and T cells [99,100]. Particularly, neutrophils and DCs frequently co-localize at sites of infection and DCs were found to capture neutrophils that have phagocytosed *Leishmania* and underwent apoptosis, a novel mechanism, which is how this pathogen undermines adaptive immune responses [101,102]. T helper 17 (Th17) cells orchestrate neutrophil recruitment by producing IL-17 and the neutrophil chemoattractant CXCL8. Neutrophils, in turn, recruit Th17 cells via release of the chemokines CCL20 and CCL2, resulting in a positive feedback loop between neutrophils and Th17 cells [103]. In addition, neutrophils interfere with T-cell proliferation as neutrophilic myeloid-derived suppressor cells (MDSCs). Neutrophils secrete the B-cell and plasma cell survival factors “B lymphocyte stimulator” (BLyS) [104] and “A proliferation-inducing ligand” (APRIL) [105]. In turn, a subset of splenic B cells produces GM-CSF [106] that provides differentiation signals for splenic neutrophils [107]. Human splenic neutrophils have been reported to activate marginal zone B-cell class switching and T-cell-independent antibody production, suggesting a distinct “B cell-helper neutrophil” phenotype [108]. However, these findings have recently been challenged by another study in which neutrophils with characteristics of the proposed “B cell-helper neutrophil” phenotype were not found in human spleens [109].

Murine and human studies indicate that distinct neutrophil phenotypes, initially identified as low-density neutrophils in cancer patients, inhibit T and NK cell proliferation. In analogy to monocyte subsets, those suppressive neutrophilic cells have been termed granulocytic/neutrophilic MDSCs [110]. The precise cellular mechanism(s) by which MDSCs suppress T-cell responses, however, have not been fully defined, but studies indicate that arginase, ROS, indoleamine 2,3-dioxygenase (IDO), Mac-1, PD-L1, and STAT3 might be involved [110–113]. Inter-species differences appear to exist, as mechanisms identified in mice do not seem to be always transferable to the human situation. Importantly, in systemic inflammation, a distinct subset of activated CD62L^{dim} neutrophils was found to suppress T cell proliferation mediated through a Mac-1-dependent mechanism [114].

Neutrophil Defects

Inherited neutrophil defects exemplify the importance of this cell type for various infectious and non-infectious conditions. These defects comprise severe congenital neutropenia (SCN), cyclic neutropenia, CGD, leukocyte adhesion deficiencies (LADs), myeloperoxidase (MPO) deficiency, warts, hypogammablogulinaemia, infections, myelokathexis (WHIM) syndrome, specific granule deficiency, defects in toll-like receptor (TLR)/interleukin 1 receptor-associated kinase (IRAK) 4/caspase activation and recruitment domain-containing protein (CARD) 9 signalling, and other less defined entities and are summarized in the chapters below.

Severe congenital neutropenia (SCN)

In SCN, neutrophilic differentiation is blocked at the promyelocyte/myelocyte stage, leading to isolated neutropenia with frequent severe bacterial and fungal infections and requiring lifelong treatment with G-CSF. Upon G-CSF treatment, SCN patients produce low numbers of neutrophils, sufficient to protect them from infections. The majority of SCN patients harbour autosomal dominant mutations in the neutrophil elastase gene (*ELANE*) [115]. Mechanistically, it has been proposed that intracellular accumulation of misfolded mutated neutrophil elastase activates the unfolded-protein response (UPR) and endoplasmic reticulum (ER) stress [116,117] and promotes apoptosis [118]. Beyond *ELANE*, mutations in the haematopoietic cell-specific Lyn substrate (HCLS) 1-associated gene X1 (*HAX1*) were identified as a cause of neutropenia

[119]. Further studies showed that the HAX1 interaction partner HCLS1 is activated by G-CSF, leading to the activation of the myeloid-specific transcription factor lymphoid enhancer binding factor (LEF)-1 [120,121]. A small subgroup of SCN patients have mutations in the transcriptional repressor oncoprotein growth factor independent (GFI) 1 [122], cytoskeletal regulator Wiskott-Aldrich Syndrome (WAS) protein [123], glucose-6 phosphatase catalytic subunit 3 (G6P3C) [124], endosomal adaptor protein p14 (also known as MAPBPIP) [125], or the endosomal trafficking vacuolar protein sorting 45 (VPS45) [126]. Depending on the type of the inherited gene mutation, SCN patients exhibit either isolated neutropenia (*ELANE* mutations) or additional syndromes such as lymphopenia (GFI1 gene mutations); monocytopenia (WAS-mutations); mental retardation/seizures (HAX1 mutations); prominent superficial venous network, atrial defects, and uropathy (G6PC3-associated disorders); and albinism and hyper-gammaglobulinemia (p14-mutated patients).

Chronic granulomatous disease (CGD)

CGD is caused by mutations in the genes encoding the subunits of the phagocyte NADPH oxidase complex, with an incidence around 1/200,000 [127]. CGD phagocytes cannot effectively produce superoxide (O_2^-) and fail to kill ingested pathogens, leading to severe infections, mainly by *Staphylococcus* and *Aspergillus* species [127,128]. CGD disease severity correlates inversely with the remaining neutrophil ROS production capacity [129]. The majority of CGD patients show mutations in gp91^{phox}, which is the only CGD gene encoded on the X-chromosome [127–131]. X-linked CGD is characterised by an early onset and a high morbidity and mortality [128,129] and can also affect female carriers with an extreme X-chromosome inactivation pattern [132]. It has been proposed that the susceptibility of CGD patients to *Aspergillus* species might be due to a defect in ROS-dependent NET formation [59], an issue requiring further research. CGD patients exhibit a state of chronic immune activation, possibly due to diminished autophagy triggering excessive IL-1 β release [133]. As a result, autoimmune conditions, such as SLE, discoid lupus erythematosus, and rheumatoid arthritis, are more prevalent among CGD patients [127,128,134]. Obstructive gastrointestinal and genitourinary granulomas in CGD are usually not caused by infections but by chronic inflammation [135] and often coincide with colonic inflammation reminiscent of Crohn's disease [127,128,136]. This may be due to diminished intestinal epithelial defence as a result of the lack of ROS production by transmigrating CGD neutrophils [137].

Leukocyte adhesion deficiencies (LADs)

LADs are caused by several autosomal recessive genetic defects in molecules involved in the leukocyte adhesion cascade. The patients' neutrophils cannot leave the circulation, leading to infection susceptibility [138]. In LAD-I, mutations in the gene encoding CD18, the integrin β 2-chain, lead to the complete absence or decreased expression of the integrins α L β 2, α M β 2, α X β 2, and α D β 2 [139–143], rarely to normally expressed, but dysfunctional, β 2-integrins [144]. Mutations in a Golgi guanosine diphosphate-fucose transporter (GFTP) protein, which is encoded by the *SLC35C1* (solute carrier family 35 member C1) gene, lead to LAD-II [145,146], which was reclassified as the congenital disorder of glycosylation-IIc (CDG-IIc) [147]. Patients with LAD-II develop milder infections as in LAD-I, but have other abnormalities [147–149]. LAD-III, also known as LAD-I/variant, is caused by mutations in the gene *FERMT3* (fermitin family homolog 3) encoding the β -integrin (β 1, β 2, and β 3) adaptor protein kindlin-3. LAD-III patients also suffer from platelet defects and subsequent bleeding as well as osteopetrosis-like bone defects [150–154]. A combination of a LAD-like and CGD-like phenotype was described in two patients with mutations in *Rac2* in which neutrophils showed

defective chemotaxis due to impaired actin polymerisation and impaired NADPH oxidase activation [155,156]. An exciting, novel concept has recently emerged from studies of LAD-I patients in which defective neutrophil recruitment causes inflammatory periodontal bone loss. Surprisingly, the severe bone loss in these patients was not due to a lack of control of bacterial infections, but rather to the inability to control IL-17 production, which is normally reduced by phagocytosis of locally recruited neutrophils [157]. These findings suggest that neutrophils, the prototypic proinflammatory cells, have a profound anti-inflammatory function in steady state that is mediated by their effective efferocytosis. Thus, neutralizing IL-17 may be relevant for LAD-I and other diseases in which neutrophil recruitment to peripheral tissues is defective.

WHIM syndrome

In WHIM syndrome, CXCR4 gain-of-function mutations lead to neutropenia caused by increased retention of neutrophils in the bone marrow [158]. In addition to neutropenia, these patients often have lymphopenia and monocytopenia. The concept of CXCR4-dependent release of neutrophils from the bone marrow has recently been challenged by an intravital microscopy study showing that CXCR4 inhibition using plerixafor in mice triggers mobilization of neutrophils from the marginated pool of the lung and simultaneously prevents neutrophil homing to the bone marrow [27], highlighting the lung as a rich and easily mobilized source of neutrophils. The therapeutic relevance of these findings for neutropenic patients and other diseases remains to be defined in future studies.

Defects in innate immune receptor signalling

Neutrophils express various TLRs and TLR activation triggers antibacterial effector functions [159]. Mutations in myeloid differentiation primary response (*MYD*) 88 or *IRAK4*, central downstream mediators of TLR signalling, lead to recurrent, invasive bacterial infections in infancy and early childhood. This susceptibility decreases with age, so TLR-mediated signalling in neutrophils seems rather dispensable beyond adolescence. Neutrophils of these patients do not respond to TLR and IL-1R ligation, whereas ROS production is normal [160,161]. Acute-phase responses are delayed or even absent despite severe infections [162–166]. Mutations in *CARD9*, a protein essential for the sensing of fungi, lead to *Candida* infections [167], which was recently linked to impaired neutrophil killing [168]. Mutations in proteins regulating the activity of nuclear factor (NF) κ B, namely NF κ B essential modulator (NEMO) and inhibitor of NF κ B kinase (IKK) α , lead to immunodeficiency in combination with other symptoms [166].

Specific Granule and MPO deficiency

Patients with specific-granule deficiency are extremely rare and suffer from recurrent bacterial infections due to a lack of secondary and tertiary granule proteins [169]. Specific-granule deficiency is caused by mutations in the transcription factor CCAAT/enhancer-binding protein ϵ (CEBPE), which is an important transcriptional regulator of granulopoiesis at the late stages of differentiation. Inherited MPO deficiency is frequent in humans, but MPO-deficient individuals are mostly asymptomatic, except for a small subset that suffers from diabetes [170].

Neutrophils in Acute Inflammation

Neutrophils are the first cells recruited to sites of infection and inflammation and, therefore, play a key role in several forms of acute inflammation, a topic that goes beyond the scope of this review. Here, we highlight several recent findings in this field and refer for further information to previous, more comprehensive reviews [171–174]. Neutrophil recruitment and

activation are key events in acute inflammatory conditions, such as acute lung injury, and essential to provide a first cellular shield against bacterial and fungal pathogens. Neutrophil infiltration is not limited to infectious conditions and also occurs in sterile environments, mediated by a multistep migratory sequence, involving the inflammasome, chemokines, and formyl-peptide signals [175]. Physiologically, acute neutrophilic inflammation is followed by a resolution phase [176], important for tissue homeostasis. If these resolving mechanisms fail, neutrophils drive chronic inflammation, characterized by oxidant and protease release and leading to tissue injury. Consequently, a precise understanding of the local fine-tuning of neutrophil activation at sites of inflammation is mandatory. Full-blown neutrophil activation generally requires a two-step process, initiated by preactivation/priming through proinflammatory cytokines, such as tumor necrosis factor (TNF) α , IL-1 β , IL-8, leukotriene (LT)B4 or GM-CSF, or bacterial products and by a later second-hit stimulus [177]. Priming is not a terminal event, as neutrophils can undergo cycles of priming and de-priming [178]. Importantly, the lung has been demonstrated recently to be a place for retention of primed neutrophils, a protective mechanism shown to be impaired in acute respiratory distress syndrome (ARDS) [28,179]. While various stimulants of neutrophil activity have been established, negative regulators are poorly defined. A recent study demonstrates that the sialic acid binding Ig-like lectin E (siglec-E) acts as an important negative regulator of neutrophil recruitment to the lung [180]. The NADPH oxidase, well known as the major source of ROS, has paradoxically also been shown to limit inflammation [134], yet the underlying mechanisms remained poorly defined. Davidson and co-workers now show that the NADPH oxidase dampened neutrophilic inflammation and was protective against acute lung injury by activating nuclear factor erythroid 2-related factor 2 (Nrf2), a transcriptional factor inducing antioxidative and cytoprotective pathways and suggesting Nrf2 as a novel anti-inflammatory therapeutic target [181]. Other recently described mechanisms in acute neutrophilic inflammation include the pulmonary endothelial glycocalyx [182] and myeloid-related protein-14 [183] in sepsis, midkine [184], hematopoietic progenitor kinase 1 (HPK1) [185], and chitinase-like proteins [186].

Neutrophils in Chronic Disease and Tissue Injury

While the role of neutrophils in acute inflammation is rather well established, their complexity in chronic diseases, tissue injury, and repair has just begun to evolve. Several chronic inflammatory disease conditions are characterized by a sustained influx of neutrophils, such as CF, chronic obstructive pulmonary disease, rheumatoid arthritis, nephritis, SLE, and cardiovascular diseases. Chemokines, lipid mediators, complement fragments, and tissue breakdown products trigger the migration of neutrophils into diseased tissues. Upon local activation, transmigrated neutrophils release their toxic ingredients, proteases and oxidants, which cause tissue injury and drive the production of chemokines that feed into the neutrophil recruitment loop. Neutrophil-derived serine and matrix metalloproteases (MMPs) cleave extracellular matrix (ECM; elastin and collagen) and impair host defence by degrading immune receptors and collectins. Neutrophils are a prominent source of MMPs, particularly MMP-9, thereby contributing to tissue damage and remodelling [187]. Consequently, neutrophil activities lead to cleavage of ECM into small fragments that, in turn, can stimulate the immune system and feed a positive feedback loop of tissue destruction and immune cell infiltration. Central to tissue injury and repair circuits is the tripeptide proline–glycine–proline (PGP), which is generated through the concerted action of several neutrophil-derived proteases, particularly MMP-8, MMP-9, and prolyl endopeptidase (PE). PGP can act as a chemokine mimetic and triggers neutrophil migration through CXCR1 and CXCR2 [188]. PGP is inactivated through a non-canonical functionality of the enzyme leukotriene A4 hydrolase (LTA4H) [189]. Persistence of

PGP has been found in several neutrophilic diseases, including CF lung disease. Another neutrophil-derived protein involved in inflammation and tissue remodeling is high mobility group box protein-1 (HMGB1), a chromatin protein released from necrotic neutrophils and activating receptor for advanced glycation endproducts (RAGE) TLR and CXCR4 [190,191].

Neutrophil Heterogeneity and Plasticity

Heterogeneity of neutrophils is found at several levels: (i) nuclear appearance (band cells, mature and hypersegmented neutrophils); (ii) density (“low”-MDSCs versus “high” conventional density neutrophils [192]); (iii) NET-releasing versus non-NET-releasing neutrophils; and (iv) receptor expression profiles associated with distinct neutrophil subsets, which are summarized below:

- Olfactomedin 4-expressing neutrophils, associated with a NET-releasing neutrophil subtype [87]
- CD177 (NB1)-expressing neutrophils, associated with proteinase 3 and autoimmune diseases [193]
- CD16^{bright}CD62L^{dim} for suppressive neutrophils in systemic inflammation [114]
- CD66b/CD33-expressing low-density neutrophils for neutrophilic MDSCs [192]
- CXCR4⁺ for aged/senescent neutrophils [194]
- CD63-expressing neutrophils in the airways of patients with CF [195]
- CD49d-expressing neutrophils in atopic individuals [196]
- VEGF-induced MMP-9 expressing “pro-angiogenic” neutrophils [187]
- Neutrophils expressing a T-cell receptor-associated variable immunoreceptor complex [197]
- ICAM-1/CD54-expressing neutrophils associated with systemic inflammation and reverse migration [23,198]
- N1/N2 tumor-associated neutrophils (TANs) in murine tumor models (antitumorigenic, proinflammatory N1 neutrophils; protumorigenic, immunosuppressive N2 neutrophils) [199]
- PMN-I (producing IL-12 and CCL3, inducing classically-activated macrophages) conferring protection against methicillin-resistant *S. aureus* (MRSA) infection and PMN-II (producing IL-10 and CCL2, inducing alternatively-activated macrophages) conferring susceptibility for MRSA infection [200]

The disease associations and functional characteristics of these described neutrophil phenotypes remain to be established. Could these markers be useful for subtyping different harmful versus beneficial neutrophil subsets at sites of chronic inflammation? Further studies in humans and mouse models are required to link phenotypic characteristics with functions.

Beyond heterogeneity, the potential of neutrophils to undergo phenotypic and/or functional plasticity has been addressed by some studies, demonstrating that neutrophils can transdifferentiate into: (i) DC-neutrophil hybrids upon GM-CSF stimulation with phenotypic and functional characteristics of both neutrophils and DCs [201,202]; (ii) DC-like cells in rheumatoid arthritis [203]; (iii) MHC-II-expressing antigen-presenting cells, induced by acidosis, cytokines, and growth factors and found in chronic inflammatory diseases [204,205]; and (iv) giant phagocytes, associated with autophagy [206]. Moreover, under inflammatory conditions,

band-stage neutrophils were recently shown to transdifferentiate into monocytes [207]. Metabolic reprogramming, including the induction of anabolic pro-survival pathways, has been described in CF airway neutrophils, including up-regulation of the mammalian target of rapamycin (mTOR) pathway [208] and nutrient/glucose transporters [209]. Monocytic MDSCs have been shown to transdifferentiate into neutrophilic MDSCs [210]. While some of these neutrophil transdifferentiation phenotypes are found in chronic inflammatory and infectious disease conditions [100,203,208], their overall disease relevance remains to be better defined.

Conclusions

Novel technologies, such as intravital microscopy and transgenic mice, have expanded our insights into neutrophil homeostasis and effector functions tremendously. Neutrophil steady-state homeostasis is not only regulated by growth factors, cytokines, and chemokines, but also involves microbial pattern recognition, linking hematopoiesis with microbiota. Neutrophil clearance seems to be even more complex, involving apoptosis/efferocytosis, reverse migration, and homing of senescent neutrophils back to the bone marrow, a process that, in turn, may regulate circadian neutrophil turnover. Besides their role as potent phagocytes, neutrophils expose their granule contents and DNA through NETosis, but its precise pathophysiological relevance *in vivo* remains to be defined. The spectrum of neutrophil plasticities has been further expanded by their role as immunomodulatory MDSCs that dampen T-cell activity. The clinical importance of neutrophils in host defence is underscored by the severity and complexity of infections in patients with inherited immunodeficiencies associated with a loss of neutrophil number or function. Faced with the emerging heterogeneity and plasticity of neutrophils, the challenge for the future remains how to target harmful, while promoting protective, neutrophil phenotypes. Based on these concepts, neutrophils in chronic inflammatory disease conditions are supposed to do more harm than good, rendering them promising therapeutic targets in chronic diseases. However, targeting neutrophils always bears the risk of increasing infection susceptibility, particularly towards bacterial and fungal pathogens. Small-molecule CXCR2 antagonists inhibit neutrophil chemotaxis and have been used in clinical studies in CF lung disease, with limited success [211]. Beyond these universal targeting approaches, inhibiting or depleting specific harmful neutrophil subsets, while preserving beneficial subtypes, would be preferential. However, this approach is limited by our current understanding of neutrophil heterogeneity. Which markers could be useful to identify harmful neutrophil phenotypes? Future studies using small molecules or antibodies targeting distinct neutrophil subsets will be required to address this question and to move forward towards a neutrophil subtype-selective pharmacologic treatment strategy.

Acknowledgments

We thank Niels Borregaard, University of Copenhagen, and Anna-Lena Schaupp, University of Oxford, for helpful comments on the manuscript.

References

1. Rørvig S, Østergaard O, Heegaard NHH, Borregaard N (2013) Proteome profiling of human neutrophil granule subsets, secretory vesicles, and cell membrane: correlation with transcriptome profiling of neutrophil precursors. *Journal of Leukocyte Biology* 94: 711–721. doi: [10.1189/jlb.1212619](https://doi.org/10.1189/jlb.1212619) PMID: [23650620](https://pubmed.ncbi.nlm.nih.gov/23650620/)
2. Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC (2002) G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. *Immunity* 17: 413–423. PMID: [12387736](https://pubmed.ncbi.nlm.nih.gov/12387736/)

3. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, et al. (2010) Neutrophil kinetics in health and disease. *Trends Immunol* 31: 318–324. doi: [10.1016/j.it.2010.05.006](https://doi.org/10.1016/j.it.2010.05.006) PMID: [20620114](https://pubmed.ncbi.nlm.nih.gov/20620114/)
4. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, et al. (1994) Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. *Blood* 84: 1737–1746. PMID: [7521686](https://pubmed.ncbi.nlm.nih.gov/7521686/)
5. Basu S, Hodgson G, Katz M, Dunn AR (2002) Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation. *Blood* 100: 854–861. PMID: [12130495](https://pubmed.ncbi.nlm.nih.gov/12130495/)
6. Hibbs ML, Quilici C, Kountouri N, Seymour JF, Armes JE, et al. (2007) Mice lacking three myeloid colony-stimulating factors (G-CSF, GM-CSF, and M-CSF) still produce macrophages and granulocytes and mount an inflammatory response in a sterile model of peritonitis. *J Immunol* 178: 6435–6443. PMID: [17475873](https://pubmed.ncbi.nlm.nih.gov/17475873/)
7. Christopher MJ, Link DC (2007) Regulation of neutrophil homeostasis. *Curr Opin Hematol* 14: 3–8. PMID: [17133093](https://pubmed.ncbi.nlm.nih.gov/17133093/)
8. Luo HR, Loison F (2008) Constitutive neutrophil apoptosis: mechanisms and regulation. *Am J Hematol* 83: 288–295. PMID: [17924549](https://pubmed.ncbi.nlm.nih.gov/17924549/)
9. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, et al. (2005) Phagocytosis of Apoptotic Neutrophils Regulates Granulopoiesis via IL-23 and IL-17. *Immunity* 22: 285–294. PMID: [15780986](https://pubmed.ncbi.nlm.nih.gov/15780986/)
10. Rozman S, Yousefi S, Oberson K, Kaufmann T, Benarafa C, et al. (2014) The generation of neutrophils in the bone marrow is controlled by autophagy. *Cell Death Differ*.
11. Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, et al. (2003) Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. *Immunity* 19: 583–593. PMID: [14563322](https://pubmed.ncbi.nlm.nih.gov/14563322/)
12. Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, et al. (2010) SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. *Eur Respir J* 35: 564–570. doi: [10.1183/09031936.00048509](https://doi.org/10.1183/09031936.00048509) PMID: [19643947](https://pubmed.ncbi.nlm.nih.gov/19643947/)
13. Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, et al. (2011) SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. *Br J Clin Pharmacol* 72: 282–293. doi: [10.1111/j.1365-2125.2011.03968.x](https://doi.org/10.1111/j.1365-2125.2011.03968.x) PMID: [21426372](https://pubmed.ncbi.nlm.nih.gov/21426372/)
14. Virtala R, Ekman AK, Jansson L, Westin U, Cardell LO (2012) Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. *Clin Exp Allergy* 42: 590–596. doi: [10.1111/j.1365-2222.2011.03921.x](https://doi.org/10.1111/j.1365-2222.2011.03921.x) PMID: [22192144](https://pubmed.ncbi.nlm.nih.gov/22192144/)
15. Leaker BR, Barnes PJ, O'Connor B (2013) Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. *Respir Res* 14: 137. doi: [10.1186/1465-9921-14-137](https://doi.org/10.1186/1465-9921-14-137) PMID: [24341382](https://pubmed.ncbi.nlm.nih.gov/24341382/)
16. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, et al. (2012) Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. *Clin Exp Allergy* 42: 1097–1103. doi: [10.1111/j.1365-2222.2012.04014.x](https://doi.org/10.1111/j.1365-2222.2012.04014.x) PMID: [22702508](https://pubmed.ncbi.nlm.nih.gov/22702508/)
17. Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, et al. (2013) Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. *J Cyst Fibros* 12: 241–248. doi: [10.1016/j.jcf.2012.08.016](https://doi.org/10.1016/j.jcf.2012.08.016) PMID: [22995323](https://pubmed.ncbi.nlm.nih.gov/22995323/)
18. Vandivier RW, Henson PM, Douglas IS (2006) Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. *Chest* 129: 1673–1682. PMID: [16778289](https://pubmed.ncbi.nlm.nih.gov/16778289/)
19. A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, et al. (2009) Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. *Immunity* 31: 245–258. doi: [10.1016/j.immuni.2009.06.018](https://doi.org/10.1016/j.immuni.2009.06.018) PMID: [19646905](https://pubmed.ncbi.nlm.nih.gov/19646905/)
20. Hong C, Kidani Y, A-Gonzalez N, Phung T, Ito A, et al. (2012) Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. *J Clin Invest* 122: 337–347. doi: [10.1172/JCI58393](https://doi.org/10.1172/JCI58393) PMID: [22156197](https://pubmed.ncbi.nlm.nih.gov/22156197/)
21. Furze RC, Rankin SM (2008) The role of the bone marrow in neutrophil clearance under homeostatic conditions in the mouse. *FASEB J* 22: 3111–3119. doi: [10.1096/fj.08-109876](https://doi.org/10.1096/fj.08-109876) PMID: [18509199](https://pubmed.ncbi.nlm.nih.gov/18509199/)
22. Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chevre R, et al. (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. *Cell* 153: 1025–1035. doi: [10.1016/j.cell.2013.04.040](https://doi.org/10.1016/j.cell.2013.04.040) PMID: [23706740](https://pubmed.ncbi.nlm.nih.gov/23706740/)
23. Buckley CD, Ross EA, McGettrick HM, Osborne CE, Haworth O, et al. (2006) Identification of a phenotypically and functionally distinct population of long-lived neutrophils in a model of reverse endothelial migration. *J Leukoc Biol* 79: 303–311. PMID: [16330528](https://pubmed.ncbi.nlm.nih.gov/16330528/)

24. Woodfin A, Voisin MB, Beyrau M, Colom B, Caille D, et al. (2011) The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. *Nat Immunol* 12: 761–769. doi: [10.1038/ni.2062](https://doi.org/10.1038/ni.2062) PMID: [21706006](https://pubmed.ncbi.nlm.nih.gov/21706006/)
25. Shelef MA, Tauzin S, Huttenlocher A (2013) Neutrophil migration: moving from zebrafish models to human autoimmunity. *Immunol Rev* 256: 269–281. doi: [10.1111/immr.12124](https://doi.org/10.1111/immr.12124) PMID: [24117827](https://pubmed.ncbi.nlm.nih.gov/24117827/)
26. Athens JW, Haab OP, Raab SO, Mauer AM, Ashenbrucker H, et al. (1961) Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. *J Clin Invest* 40: 989–995. PMID: [13684958](https://pubmed.ncbi.nlm.nih.gov/13684958/)
27. Devi S, Wang Y, Chew WK, Lima R, A-González N, et al. (2013) Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow. *The Journal of Experimental Medicine* 210: 2321–2336. doi: [10.1084/jem.20130056](https://doi.org/10.1084/jem.20130056) PMID: [24081949](https://pubmed.ncbi.nlm.nih.gov/24081949/)
28. Summers C, Singh NR, White JF, Mackenzie IM, Johnston A, et al. (2014) Pulmonary retention of primed neutrophils: a novel protective host response, which is impaired in the acute respiratory distress syndrome. *Thorax* 69: 623–629. doi: [10.1136/thoraxjnl-2013-204742](https://doi.org/10.1136/thoraxjnl-2013-204742) PMID: [24706039](https://pubmed.ncbi.nlm.nih.gov/24706039/)
29. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, et al. (2010) In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. *Blood* 116: 625–627. doi: [10.1182/blood-2010-01-259028](https://doi.org/10.1182/blood-2010-01-259028) PMID: [20410504](https://pubmed.ncbi.nlm.nih.gov/20410504/)
30. Tofts PS, Chevassut T, Cutajar M, Dowell NG, Peters AM (2011) Doubts concerning the recently reported human neutrophil lifespan of 5.4 days. *Blood* 117: 6050–6052; author reply 6053–6054. doi: [10.1182/blood-2010-10-310532](https://doi.org/10.1182/blood-2010-10-310532) PMID: [21636720](https://pubmed.ncbi.nlm.nih.gov/21636720/)
31. Li KW, Turner SM, Emson CL, Hellerstein MK, Dale DC (2011) Deuterium and neutrophil kinetics. *Blood* 117: 6052–6053; author reply 6053–6054. doi: [10.1182/blood-2010-12-322271](https://doi.org/10.1182/blood-2010-12-322271) PMID: [21636721](https://pubmed.ncbi.nlm.nih.gov/21636721/)
32. Pham CT (2006) Neutrophil serine proteases: specific regulators of inflammation. *Nat Rev Immunol* 6: 541–550. PMID: [16799473](https://pubmed.ncbi.nlm.nih.gov/16799473/)
33. Borregaard N (2010) Neutrophils, from marrow to microbes. *Immunity* 33: 657–670. doi: [10.1016/j.immuni.2010.11.011](https://doi.org/10.1016/j.immuni.2010.11.011) PMID: [21094463](https://pubmed.ncbi.nlm.nih.gov/21094463/)
34. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F (2010) Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. *Pharmacol Rev* 62: 726–759. doi: [10.1124/pr.110.002733](https://doi.org/10.1124/pr.110.002733) PMID: [21079042](https://pubmed.ncbi.nlm.nih.gov/21079042/)
35. Benarafa C, LeCuyer TE, Baumann M, Stolley JM, Cremona TP, et al. (2011) SerpinB1 protects the mature neutrophil reserve in the bone marrow. *J Leukoc Biol* 90: 21–29. doi: [10.1189/jlb.0810461](https://doi.org/10.1189/jlb.0810461) PMID: [21248149](https://pubmed.ncbi.nlm.nih.gov/21248149/)
36. Benarafa C, Priebe GP, Remold-O'Donnell E (2007) The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in *Pseudomonas aeruginosa* infection. *J Exp Med* 204: 1901–1909. PMID: [17664292](https://pubmed.ncbi.nlm.nih.gov/17664292/)
37. Gong D, Farley K, White M, Hartshorn KL, Benarafa C, et al. (2011) Critical role of serpinB1 in regulating inflammatory responses in pulmonary influenza infection. *J Infect Dis* 204: 592–600. doi: [10.1093/infdis/jir352](https://doi.org/10.1093/infdis/jir352) PMID: [21791661](https://pubmed.ncbi.nlm.nih.gov/21791661/)
38. Baumann M, Pham CT, Benarafa C (2013) SerpinB1 is critical for neutrophil survival through cell-autonomous inhibition of cathepsin G. *Blood* 121: 3900–3907, S3901–3906. doi: [10.1182/blood-2012-09-455022](https://doi.org/10.1182/blood-2012-09-455022) PMID: [23532733](https://pubmed.ncbi.nlm.nih.gov/23532733/)
39. Loison F, Zhu H, Karatepe K, Kasorn A, Liu P, et al. (2014) Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation. *J Clin Invest* 124: 4445–4458. doi: [10.1172/JCI76246](https://doi.org/10.1172/JCI76246) PMID: [25180606](https://pubmed.ncbi.nlm.nih.gov/25180606/)
40. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, et al. (2004) Neutrophil extracellular traps kill bacteria. *Science* 303: 1532–1535. PMID: [15001782](https://pubmed.ncbi.nlm.nih.gov/15001782/)
41. Mitroulis I, Kourtzelis I, Kambas K, Rafail S, Chrysanthopoulou A, et al. (2010) Regulation of the autophagic machinery in human neutrophils. *Eur J Immunol* 40: 1461–1472. doi: [10.1002/eji.200940025](https://doi.org/10.1002/eji.200940025) PMID: [20162553](https://pubmed.ncbi.nlm.nih.gov/20162553/)
42. Mihalache CC, Simon HU (2012) Autophagy regulation in macrophages and neutrophils. *Exp Cell Res* 318: 1187–1192. doi: [10.1016/j.yexcr.2011.12.021](https://doi.org/10.1016/j.yexcr.2011.12.021) PMID: [22245582](https://pubmed.ncbi.nlm.nih.gov/22245582/)
43. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, et al. (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. *Proc Natl Acad Sci U S A* 107: 9813–9818. doi: [10.1073/pnas.0909927107](https://doi.org/10.1073/pnas.0909927107) PMID: [20439745](https://pubmed.ncbi.nlm.nih.gov/20439745/)
44. Yipp BG, Petri B, Salina D, Jenne CN, Scott BN, et al. (2012) Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. *Nat Med* 18: 1386–1393. PMID: [22922410](https://pubmed.ncbi.nlm.nih.gov/22922410/)

45. Harding MG, Zhang K, Conly J, Kubes P (2014) Neutrophil Crawling in Capillaries; A Novel Immune Response to *Staphylococcus aureus*. *PLoS Pathog* 10: e1004379. doi: [10.1371/journal.ppat.1004379](https://doi.org/10.1371/journal.ppat.1004379) PMID: [25299673](https://pubmed.ncbi.nlm.nih.gov/25299673/)
46. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P (2012) Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. *Cell Host Microbe* 12: 324–333. doi: [10.1016/j.chom.2012.06.011](https://doi.org/10.1016/j.chom.2012.06.011) PMID: [22980329](https://pubmed.ncbi.nlm.nih.gov/22980329/)
47. Jenne CN, Wong CH, Zemp FJ, McDonald B, Rahman MM, et al. (2013) Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. *Cell Host Microbe* 13: 169–180. doi: [10.1016/j.chom.2013.01.005](https://doi.org/10.1016/j.chom.2013.01.005) PMID: [23414757](https://pubmed.ncbi.nlm.nih.gov/23414757/)
48. Rada BK, Geiszt M, Kaldi K, Timar C, Ligeti E (2004) Dual role of phagocytic NADPH oxidase in bacterial killing. *Blood* 104: 2947–2953. PMID: [15251984](https://pubmed.ncbi.nlm.nih.gov/15251984/)
49. Reeves EP, Lu H, Jacobs HL, Messina CGM, Bolsover S, et al. (2002) Killing activity of neutrophils is mediated through activation of proteases by K⁺ flux. *Nature* 416: 291–297. PMID: [11907569](https://pubmed.ncbi.nlm.nih.gov/11907569/)
50. Roos D, Winterbourn CC (2002) Immunology. Lethal weapons. *Science* 296: 669–671. PMID: [11976433](https://pubmed.ncbi.nlm.nih.gov/11976433/)
51. Sørensen OE, Clemmensen SN, Dahl SL, Ostergaard O, Heegaard NH, et al. (2014) Papillon-Lefevre syndrome patient reveals species-dependent requirements for neutrophil defenses. *J Clin Invest* 124: 4539–4548. doi: [10.1172/JCI76009](https://doi.org/10.1172/JCI76009) PMID: [25244098](https://pubmed.ncbi.nlm.nih.gov/25244098/)
52. Gerber CE, Bruchelt G, Falk UB, Kimpfler A, Hauschild O, et al. (2001) Reconstitution of bactericidal activity in chronic granulomatous disease cells by glucose-oxidase-containing liposomes. *Blood* 98: 3097–3105. PMID: [11698296](https://pubmed.ncbi.nlm.nih.gov/11698296/)
53. Nakamura H, Fang J, Mizukami T, Nunoi H, Maeda H (2012) PEGylated d-amino acid oxidase restores bactericidal activity of neutrophils in chronic granulomatous disease via hypochlorite. *Experimental Biology and Medicine* 237: 703–708. doi: [10.1258/ebm.2012.011360](https://doi.org/10.1258/ebm.2012.011360) PMID: [22715431](https://pubmed.ncbi.nlm.nih.gov/22715431/)
54. Standish AJ, Weiser JN (2009) Human neutrophils kill *Streptococcus pneumoniae* via serine proteases. *J Immunol* 183: 2602–2609. doi: [10.4049/jimmunol.0900688](https://doi.org/10.4049/jimmunol.0900688) PMID: [19620298](https://pubmed.ncbi.nlm.nih.gov/19620298/)
55. Sokolovska A, Becker CE, Ip WK, Rathinam VA, Brudner M, et al. (2013) Activation of caspase-1 by the NLRP3 inflammasome regulates the NADPH oxidase NOX2 to control phagosome function. *Nat Immunol* 14: 543–553. doi: [10.1038/ni.2595](https://doi.org/10.1038/ni.2595) PMID: [23644505](https://pubmed.ncbi.nlm.nih.gov/23644505/)
56. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, et al. (2007) Novel cell death program leads to neutrophil extracellular traps. *J Cell Biol* 176: 231–241. PMID: [17210947](https://pubmed.ncbi.nlm.nih.gov/17210947/)
57. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A (2010) Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. *J Cell Biol* 191: 677–691. doi: [10.1083/jcb.201006052](https://doi.org/10.1083/jcb.201006052) PMID: [20974816](https://pubmed.ncbi.nlm.nih.gov/20974816/)
58. Yousefi S, Mihalache C, Kozłowski E, Schmid I, Simon HU (2009) Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. *Cell Death Differ* 16: 1438–1444. doi: [10.1038/cdd.2009.96](https://doi.org/10.1038/cdd.2009.96) PMID: [19609275](https://pubmed.ncbi.nlm.nih.gov/19609275/)
59. Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, et al. (2009) Restoration of NET formation by gene therapy in CGD controls aspergillosis. *Blood* 114: 2619–2622. doi: [10.1182/blood-2009-05-221606](https://doi.org/10.1182/blood-2009-05-221606) PMID: [19541821](https://pubmed.ncbi.nlm.nih.gov/19541821/)
60. Piłszczek FH, Salina D, Poon KK, Fahey C, Yipp BG, et al. (2010) A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to *Staphylococcus aureus*. *J Immunol* 185: 7413–7425. doi: [10.4049/jimmunol.1000675](https://doi.org/10.4049/jimmunol.1000675) PMID: [21098229](https://pubmed.ncbi.nlm.nih.gov/21098229/)
61. Parker H, Draganow M, Hampton MB, Kettle AJ, Winterbourn CC (2012) Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap formation differ depending on the stimulus. *Journal of Leukocyte Biology* 92: 841–849. doi: [10.1189/jlb.1211601](https://doi.org/10.1189/jlb.1211601) PMID: [22802447](https://pubmed.ncbi.nlm.nih.gov/22802447/)
62. Byrd AS, O'Brien XM, Johnson CM, Lavigne LM, Reichner JS (2013) An extracellular matrix-based mechanism of rapid neutrophil extracellular trap formation in response to *Candida albicans*. *J Immunol* 190: 4136–4148. doi: [10.4049/jimmunol.1202671](https://doi.org/10.4049/jimmunol.1202671) PMID: [23509360](https://pubmed.ncbi.nlm.nih.gov/23509360/)
63. Arai Y, Nishinaka Y, Arai T, Morita M, Mizugishi K, et al. (2014) Uric acid induces NADPH oxidase-independent neutrophil extracellular trap formation. *Biochem Biophys Res Commun* 443: 556–561. doi: [10.1016/j.bbrc.2013.12.007](https://doi.org/10.1016/j.bbrc.2013.12.007) PMID: [24326071](https://pubmed.ncbi.nlm.nih.gov/24326071/)
64. Wang Y, Li M, Stadler S, Correll S, Li P, et al. (2009) Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. *J Cell Biol* 184: 205–213. doi: [10.1083/jcb.200806072](https://doi.org/10.1083/jcb.200806072) PMID: [19153223](https://pubmed.ncbi.nlm.nih.gov/19153223/)
65. Hakkim A, Fuchs TA, Martinez NE, Hess S, Prinz H, et al. (2011) Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. *Nat Chem Biol* 7: 75–77. doi: [10.1038/nchembio.496](https://doi.org/10.1038/nchembio.496) PMID: [21170021](https://pubmed.ncbi.nlm.nih.gov/21170021/)

66. Remijnsen Q, Vanden Berghe T, Wirawan E, Asselbergh B, Parthoens E, et al. (2011) Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. *Cell Res* 21: 290–304. doi: [10.1038/cr.2010.150](https://doi.org/10.1038/cr.2010.150) PMID: [21060338](https://pubmed.ncbi.nlm.nih.gov/21060338/)
67. Sumby P, Barbian KD, Gardner DJ, Whitney AR, Welty DM, et al. (2005) Extracellular deoxyribonuclease made by group A *Streptococcus* assists pathogenesis by enhancing evasion of the innate immune response. *Proc Natl Acad Sci U S A* 102: 1679–1684. PMID: [15668390](https://pubmed.ncbi.nlm.nih.gov/15668390/)
68. Beiter K, Wartha F, Albiger B, Normark S, Zychlinsky A, et al. (2006) An endonuclease allows *Streptococcus pneumoniae* to escape from neutrophil extracellular traps. *Curr Biol* 16: 401–407. PMID: [16488875](https://pubmed.ncbi.nlm.nih.gov/16488875/)
69. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, et al. (2007) DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. *Nat Med* 13: 981–985. PMID: [17632528](https://pubmed.ncbi.nlm.nih.gov/17632528/)
70. Menegazzi R, Declava E, Dri P (2012) Killing by neutrophil extracellular traps: fact or folklore? *Blood* 119: 1214–1216. doi: [10.1182/blood-2011-07-364604](https://doi.org/10.1182/blood-2011-07-364604) PMID: [22210873](https://pubmed.ncbi.nlm.nih.gov/22210873/)
71. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, et al. (2009) Netting neutrophils in autoimmune small-vessel vasculitis. *Nat Med* 15: 623–625. doi: [10.1038/nm.1959](https://doi.org/10.1038/nm.1959) PMID: [19448636](https://pubmed.ncbi.nlm.nih.gov/19448636/)
72. Thomas GM, Carbo C, Curtis BR, Martinod K, Mazo IB, et al. (2012) Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. *Blood* 119: 6335–6343. doi: [10.1182/blood-2012-01-405183](https://doi.org/10.1182/blood-2012-01-405183) PMID: [22596262](https://pubmed.ncbi.nlm.nih.gov/22596262/)
73. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, et al. (2012) Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. *J Clin Invest* 122: 2661–2671. doi: [10.1172/JCI61303](https://doi.org/10.1172/JCI61303) PMID: [22684106](https://pubmed.ncbi.nlm.nih.gov/22684106/)
74. Doring Y, Manthey HD, Drechsler M, Lievens D, Megens RT, et al. (2012) Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. *Circulation* 125: 1673–1683. doi: [10.1161/CIRCULATIONAHA.111.046755](https://doi.org/10.1161/CIRCULATIONAHA.111.046755) PMID: [22388324](https://pubmed.ncbi.nlm.nih.gov/22388324/)
75. Liu CL, Tangsombatvisit S, Rosenberg JM, Mandelbaum G, Gillespie EC, et al. (2012) Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. *Arthritis Res Ther* 14: R25. doi: [10.1186/ar3707](https://doi.org/10.1186/ar3707) PMID: [22300536](https://pubmed.ncbi.nlm.nih.gov/22300536/)
76. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, et al. (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. *Sci Transl Med* 5: 178ra140.
77. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, et al. (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat Med* 16: 887–896. doi: [10.1038/nm.2184](https://doi.org/10.1038/nm.2184) PMID: [20676107](https://pubmed.ncbi.nlm.nih.gov/20676107/)
78. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, et al. (2010) Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci U S A* 107: 15880–15885. doi: [10.1073/pnas.1005743107](https://doi.org/10.1073/pnas.1005743107) PMID: [20798043](https://pubmed.ncbi.nlm.nih.gov/20798043/)
79. von Brühl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, et al. (2012) Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. *J Exp Med* 209: 819–835. doi: [10.1084/jem.20112322](https://doi.org/10.1084/jem.20112322) PMID: [22451716](https://pubmed.ncbi.nlm.nih.gov/22451716/)
80. Martinod K, Demers M, Fuchs TA, Wong SL, Brill A, et al. (2013) Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. *Proc Natl Acad Sci U S A* 110: 8674–8679. doi: [10.1073/pnas.1301059110](https://doi.org/10.1073/pnas.1301059110) PMID: [23650392](https://pubmed.ncbi.nlm.nih.gov/23650392/)
81. Schauer C, Janko C, Munoz LE, Zhao Y, Kienhofer D, et al. (2014) Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. *Nat Med* 20: 511–517. doi: [10.1038/nm.3547](https://doi.org/10.1038/nm.3547) PMID: [24784231](https://pubmed.ncbi.nlm.nih.gov/24784231/)
82. Villanueva E, Yalavarthi S, Berthier CC, Hodgins JB, Khandpur R, et al. (2011) Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. *J Immunol* 187: 538–552. doi: [10.4049/jimmunol.1100450](https://doi.org/10.4049/jimmunol.1100450) PMID: [21613614](https://pubmed.ncbi.nlm.nih.gov/21613614/)
83. Papayannopoulos V, Staab D, Zychlinsky A (2011) Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy. *PLoS One* 6: e28526. doi: [10.1371/journal.pone.0028526](https://doi.org/10.1371/journal.pone.0028526) PMID: [22174830](https://pubmed.ncbi.nlm.nih.gov/22174830/)
84. Manzenreiter R, Kienberger F, Marcos V, Schilcher K, Krautgartner WD, et al. (2012) Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy. *J Cyst Fibros* 11: 84–92. doi: [10.1016/j.jcf.2011.09.008](https://doi.org/10.1016/j.jcf.2011.09.008) PMID: [21996135](https://pubmed.ncbi.nlm.nih.gov/21996135/)
85. Yipp BG, Kubes P (2013) NETosis: how vital is it? *Blood* 122: 2784–2794. doi: [10.1182/blood-2013-04-457671](https://doi.org/10.1182/blood-2013-04-457671) PMID: [24009232](https://pubmed.ncbi.nlm.nih.gov/24009232/)

86. Branzk N, Lubojemska A, Hardison SE, Wang Q, Gutierrez MG, et al. (2014) Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. *Nat Immunol* 15: 1017–1025. doi: [10.1038/ni.2987](https://doi.org/10.1038/ni.2987) PMID: [25217981](https://pubmed.ncbi.nlm.nih.gov/25217981/)
87. Welin A, Amirbeagi F, Christenson K, Bjorkman L, Bjornsdottir H, et al. (2013) The human neutrophil subsets defined by the presence or absence of OLFM4 both transmigrate into tissue in vivo and give rise to distinct NETs in vitro. *PLoS One* 8: e69575. doi: [10.1371/journal.pone.0069575](https://doi.org/10.1371/journal.pone.0069575) PMID: [23922742](https://pubmed.ncbi.nlm.nih.gov/23922742/)
88. Peschel A, Hartl D (2012) Anuclear neutrophils keep hunting. *Nat Med* 18: 1336–1338. doi: [10.1038/nm.2918](https://doi.org/10.1038/nm.2918) PMID: [22961160](https://pubmed.ncbi.nlm.nih.gov/22961160/)
89. Peters BM, Shirliff ME, Jabra-Rizk MA (2010) Antimicrobial peptides: primeval molecules or future drugs? *PLoS Pathog* 6: e1001067. doi: [10.1371/journal.ppat.1001067](https://doi.org/10.1371/journal.ppat.1001067) PMID: [21060861](https://pubmed.ncbi.nlm.nih.gov/21060861/)
90. Ohkubo T, Tsuda M, Tamura M, Yamamura M (1990) Impaired superoxide production in peripheral blood neutrophils of germ-free rats. *Scand J Immunol* 32: 727–729. PMID: [1702900](https://pubmed.ncbi.nlm.nih.gov/1702900/)
91. Deshmukh HS, Liu Y, Menkiti OR, Mei J, Dai N, et al. (2014) The microbiota regulates neutrophil homeostasis and host resistance to *Escherichia coli* K1 sepsis in neonatal mice. *Nat Med* 20: 524–530. doi: [10.1038/nm.3542](https://doi.org/10.1038/nm.3542) PMID: [24747744](https://pubmed.ncbi.nlm.nih.gov/24747744/)
92. Kanther M, Tomkovich S, Xiaolun S, Grosser MR, Koo J, et al. (2014) Commensal microbiota stimulate systemic neutrophil migration through induction of serum amyloid A. *Cell Microbiol* 16: 1053–1067. doi: [10.1111/cmi.12257](https://doi.org/10.1111/cmi.12257) PMID: [24373309](https://pubmed.ncbi.nlm.nih.gov/24373309/)
93. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, et al. (2010) Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. *Nat Med* 16: 228–231. doi: [10.1038/nm.2087](https://doi.org/10.1038/nm.2087) PMID: [20081863](https://pubmed.ncbi.nlm.nih.gov/20081863/)
94. Bugl S, Wirths S, Radsak MP, Schild H, Stein P, et al. (2013) Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. *Blood* 121: 723–733. doi: [10.1182/blood-2012-05-429589](https://doi.org/10.1182/blood-2012-05-429589) PMID: [23223360](https://pubmed.ncbi.nlm.nih.gov/23223360/)
95. Balmer ML, Schurch CM, Saito Y, Geuking MB, Li H, et al. (2014) Microbiota-Derived Compounds Drive Steady-State Granulopoiesis via MyD88/TICAM Signaling. *J Immunol* 193: 5273–5283. doi: [10.4049/jimmunol.1400762](https://doi.org/10.4049/jimmunol.1400762) PMID: [25305320](https://pubmed.ncbi.nlm.nih.gov/25305320/)
96. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, et al. (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* 461: 1282–1286. doi: [10.1038/nature08530](https://doi.org/10.1038/nature08530) PMID: [19865172](https://pubmed.ncbi.nlm.nih.gov/19865172/)
97. Schwabe RF, Jobin C (2013) The microbiome and cancer. *Nat Rev Cancer* 13: 800–812. doi: [10.1038/nrc3610](https://doi.org/10.1038/nrc3610) PMID: [24132111](https://pubmed.ncbi.nlm.nih.gov/24132111/)
98. Gargano LM, Hughes JM (2014) Microbial origins of chronic diseases. *Annu Rev Public Health* 35: 65–82. doi: [10.1146/annurev-publhealth-032013-182426](https://doi.org/10.1146/annurev-publhealth-032013-182426) PMID: [24365095](https://pubmed.ncbi.nlm.nih.gov/24365095/)
99. Mocsai A (2013) Diverse novel functions of neutrophils in immunity, inflammation, and beyond. *J Exp Med* 210: 1283–1299. doi: [10.1084/jem.20122220](https://doi.org/10.1084/jem.20122220) PMID: [23825232](https://pubmed.ncbi.nlm.nih.gov/23825232/)
100. Scapini P, Cassatella MA (2014) Social networking of human neutrophils within the immune system. *Blood* 124: 710–719. doi: [10.1182/blood-2014-03-453217](https://doi.org/10.1182/blood-2014-03-453217) PMID: [24923297](https://pubmed.ncbi.nlm.nih.gov/24923297/)
101. Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, et al. (2009) Vector transmission of leishmania abrogates vaccine-induced protective immunity. *PLoS Pathog* 5: e1000484. doi: [10.1371/journal.ppat.1000484](https://doi.org/10.1371/journal.ppat.1000484) PMID: [19543375](https://pubmed.ncbi.nlm.nih.gov/19543375/)
102. Ribeiro-Gomes FL, Peters NC, Debrabant A, Sacks DL (2012) Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response. *PLoS Pathog* 8: e1002536. doi: [10.1371/journal.ppat.1002536](https://doi.org/10.1371/journal.ppat.1002536) PMID: [22359507](https://pubmed.ncbi.nlm.nih.gov/22359507/)
103. Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, et al. (2010) Evidence for a cross-talk between human neutrophils and Th17 cells. *Blood* 115: 335–343. doi: [10.1182/blood-2009-04-216085](https://doi.org/10.1182/blood-2009-04-216085) PMID: [19890092](https://pubmed.ncbi.nlm.nih.gov/19890092/)
104. Scapini P, Carletto A, Nardelli B, Calzetti F, Roschke V, et al. (2005) Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. *Blood* 105: 830–837. PMID: [15358625](https://pubmed.ncbi.nlm.nih.gov/15358625/)
105. Huard B, McKee T, Bosshard C, Durual S, Matthes T, et al. (2008) APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. *J Clin Invest* 118: 2887–2895. doi: [10.1172/JCI33760](https://doi.org/10.1172/JCI33760) PMID: [18618015](https://pubmed.ncbi.nlm.nih.gov/18618015/)
106. Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, et al. (2012) Innate response activator B cells protect against microbial sepsis. *Science* 335: 597–601. doi: [10.1126/science.1215173](https://doi.org/10.1126/science.1215173) PMID: [22245738](https://pubmed.ncbi.nlm.nih.gov/22245738/)
107. Cerutti A, Puga I, Magri G (2013) The B cell helper side of neutrophils. *J Leukoc Biol* 94: 677–682. doi: [10.1189/jlb.1112596](https://doi.org/10.1189/jlb.1112596) PMID: [23630389](https://pubmed.ncbi.nlm.nih.gov/23630389/)

108. Puga I, Cols M, Barra CM, He B, Cassis L, et al. (2012) B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. *Nat Immunol* 13: 170–180. doi: [10.1038/ni.2194](https://doi.org/10.1038/ni.2194) PMID: [22197976](https://pubmed.ncbi.nlm.nih.gov/22197976/)
109. Nagelkerke SQ, aan de Kerk DJ, Jansen MH, van den Berg TK, Kuijpers TW (2014) Failure to detect functional neutrophil B helper cells in the human spleen. *PLoS One* 9: e88377. doi: [10.1371/journal.pone.0088377](https://doi.org/10.1371/journal.pone.0088377) PMID: [24523887](https://pubmed.ncbi.nlm.nih.gov/24523887/)
110. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. *Eur J Immunol* 40: 2969–2975. doi: [10.1002/eji.201040895](https://doi.org/10.1002/eji.201040895) PMID: [21061430](https://pubmed.ncbi.nlm.nih.gov/21061430/)
111. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, et al. (2005) Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. *Blood* 105: 2549–2556. PMID: [15546957](https://pubmed.ncbi.nlm.nih.gov/15546957/)
112. Kraaij MD, Savage ND, van der Kooij SW, Koekkoek K, Wang J, et al. (2010) Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. *Proc Natl Acad Sci U S A* 107: 17686–17691. doi: [10.1073/pnas.1012016107](https://doi.org/10.1073/pnas.1012016107) PMID: [20861446](https://pubmed.ncbi.nlm.nih.gov/20861446/)
113. Nagaraj S, Youn JI, Gabrilovich DI (2013) Reciprocal relationship between myeloid-derived suppressor cells and T cells. *J Immunol* 191: 17–23. doi: [10.4049/jimmunol.1300654](https://doi.org/10.4049/jimmunol.1300654) PMID: [23794702](https://pubmed.ncbi.nlm.nih.gov/23794702/)
114. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, et al. (2012) A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. *J Clin Invest* 122: 327–336. doi: [10.1172/JCI57990](https://doi.org/10.1172/JCI57990) PMID: [22156198](https://pubmed.ncbi.nlm.nih.gov/22156198/)
115. Dale DC, Person RE, Bolyard AA, Aprikyan AG, Bos C, et al. (2000) Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. *Blood* 96: 2317–2322. PMID: [11001877](https://pubmed.ncbi.nlm.nih.gov/11001877/)
116. Köllner I, Sodeik B, Schreek S, Heyn H, von Neuhoff N, et al. (2006) Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. *Blood* 108: 493–500. PMID: [16551967](https://pubmed.ncbi.nlm.nih.gov/16551967/)
117. Grenda DS, Murakami M, Ghatak J, Xia J, Boxer LA, et al. (2007) Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis. *Blood* 110: 4179–4187. PMID: [17761833](https://pubmed.ncbi.nlm.nih.gov/17761833/)
118. Carlsson G, Aprikyan AA, Tehranchi R, Dale DC, Porwit A, et al. (2004) Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. *Blood* 103: 3355–3361. PMID: [14764541](https://pubmed.ncbi.nlm.nih.gov/14764541/)
119. Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I, et al. (2007) HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). *Nat Genet* 39: 86–92. PMID: [17187068](https://pubmed.ncbi.nlm.nih.gov/17187068/)
120. Skokowa J, Cario G, Uenalan M, Schambach A, Germeshausen M, et al. (2006) LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. *Nat Med* 12: 1191–1197. PMID: [17063141](https://pubmed.ncbi.nlm.nih.gov/17063141/)
121. Skokowa J, Klimiankou M, Klimenkova O, Lan D, Gupta K, et al. (2012) Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. *Nat Med* 18: 1550–1559. doi: [10.1038/nm.2958](https://doi.org/10.1038/nm.2958) PMID: [23001182](https://pubmed.ncbi.nlm.nih.gov/23001182/)
122. Person RE, Li FQ, Duan ZJ, Benson KF, Wechsler J, et al. (2003) Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. *Nature Genetics* 34: 308–312. PMID: [12778173](https://pubmed.ncbi.nlm.nih.gov/12778173/)
123. Devriendt K, Kim AS, Mathijs G, Frints SG, Schwartz M, et al. (2001) Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. *Nat Genet* 27: 313–317. PMID: [11242115](https://pubmed.ncbi.nlm.nih.gov/11242115/)
124. Boztug K, Appaswamy G, Ashikov A, Schaffer AA, Salzer U, et al. (2009) A syndrome with congenital neutropenia and mutations in G6PC3. *N Engl J Med* 360: 32–43. doi: [10.1056/NEJMoa0805051](https://doi.org/10.1056/NEJMoa0805051) PMID: [19118303](https://pubmed.ncbi.nlm.nih.gov/19118303/)
125. Bohn G, Allroth A, Brandes G, Thiel J, Glocker E, et al. (2007) A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. *Nat Med* 13: 38–45. PMID: [17195838](https://pubmed.ncbi.nlm.nih.gov/17195838/)
126. Vilboux T, Lev A, Malicdan MC, Simon AJ, Jarvinen P, et al. (2013) A congenital neutrophil defect syndrome associated with mutations in VPS45. *N Engl J Med* 369: 54–65. doi: [10.1056/NEJMoa1301296](https://doi.org/10.1056/NEJMoa1301296) PMID: [23738510](https://pubmed.ncbi.nlm.nih.gov/23738510/)
127. Winkelstein JA, Marino MC, Johnston RB Jr., Boyle J, Curnutte J, et al. (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. *Medicine (Baltimore)* 79: 155–169. PMID: [10844935](https://pubmed.ncbi.nlm.nih.gov/10844935/)

128. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, et al. (2009) Chronic granulomatous disease: the European experience. *PLoS One* 4: e5234. doi: [10.1371/journal.pone.0005234](https://doi.org/10.1371/journal.pone.0005234) PMID: [19381301](https://pubmed.ncbi.nlm.nih.gov/19381301/)
129. Köker MY, Camcioglu Y, van Leeuwen K, Kilic SS, Barlan I, et al. (2013) Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. *J Allergy Clin Immunol*.
130. Roos D, Kuhns DB, Maddalena A, Bustamante J, Kannengiesser C, et al. (2010) Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). *Blood Cells Mol Dis* 44: 291–299. doi: [10.1016/j.bcmd.2010.01.009](https://doi.org/10.1016/j.bcmd.2010.01.009) PMID: [20167518](https://pubmed.ncbi.nlm.nih.gov/20167518/)
131. Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, et al. (2010) Hematologically important mutations: X-linked chronic granulomatous disease (third update). *Blood Cells Mol Dis* 45: 246–265. doi: [10.1016/j.bcmd.2010.07.012](https://doi.org/10.1016/j.bcmd.2010.07.012) PMID: [20729109](https://pubmed.ncbi.nlm.nih.gov/20729109/)
132. Anderson-Cohen M, Holland SM, Kuhns DB, Fleisher TA, Ding L, et al. (2003) Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation. *Clin Immunol* 109: 308–317. PMID: [14697745](https://pubmed.ncbi.nlm.nih.gov/14697745/)
133. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, et al. (2014) IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. *Proc Natl Acad Sci U S A* 111: 3526–3531. doi: [10.1073/pnas.1322831111](https://doi.org/10.1073/pnas.1322831111) PMID: [24550444](https://pubmed.ncbi.nlm.nih.gov/24550444/)
134. Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, et al. (2010) NADPH oxidase limits innate immune responses in the lungs in mice. *PLoS One* 5: e9631. doi: [10.1371/journal.pone.0009631](https://doi.org/10.1371/journal.pone.0009631) PMID: [20300512](https://pubmed.ncbi.nlm.nih.gov/20300512/)
135. Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, et al. (2004) Gastrointestinal involvement in chronic granulomatous disease. *Pediatrics* 114: 462–468. PMID: [15286231](https://pubmed.ncbi.nlm.nih.gov/15286231/)
136. Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, et al. (2008) Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. *Clin Exp Immunol* 152: 211–218. doi: [10.1111/j.1365-2249.2008.03644.x](https://doi.org/10.1111/j.1365-2249.2008.03644.x) PMID: [18410635](https://pubmed.ncbi.nlm.nih.gov/18410635/)
137. Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, et al. (2014) Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. *Immunity* 40: 66–77. doi: [10.1016/j.immuni.2013.11.020](https://doi.org/10.1016/j.immuni.2013.11.020) PMID: [24412613](https://pubmed.ncbi.nlm.nih.gov/24412613/)
138. Harris ES, Weyrich AS, Zimmerman GA (2013) Lessons from rare maladies: leukocyte adhesion deficiency syndromes. *Curr Opin Hematol* 20: 16–25. doi: [10.1097/MOH.0b013e32835a0091](https://doi.org/10.1097/MOH.0b013e32835a0091) PMID: [23207660](https://pubmed.ncbi.nlm.nih.gov/23207660/)
139. Sanchez-Madrid F, Nagy JA, Robbins E, Simon P, Springer TA (1983) A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. *J Exp Med* 158: 1785–1803. PMID: [6196430](https://pubmed.ncbi.nlm.nih.gov/6196430/)
140. Anderson DC, Schmalstieg FC, Arnaout MA, Kohl S, Tosi MF, et al. (1984) Abnormalities of polymorphonuclear leukocyte function associated with a heritable deficiency of high molecular weight surface glycoproteins (GP138): common relationship to diminished cell adherence. *J Clin Invest* 74: 536–551. PMID: [6746906](https://pubmed.ncbi.nlm.nih.gov/6746906/)
141. Springer TA, Thompson WS, Miller LJ, Schmalstieg FC, Anderson DC (1984) Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis. *J Exp Med* 160: 1901–1918. PMID: [6096477](https://pubmed.ncbi.nlm.nih.gov/6096477/)
142. Roos D, Meischl C, de Boer M, Simsek S, Weening RS, et al. (2002) Genetic analysis of patients with leukocyte adhesion deficiency: genomic sequencing reveals otherwise undetectable mutations. *Exp Hematol* 30: 252–261. PMID: [11882363](https://pubmed.ncbi.nlm.nih.gov/11882363/)
143. van de Vijver E, Maddalena A, Sanal O, Holland SM, Uzel G, et al. (2012) Hematologically important mutations: leukocyte adhesion deficiency (first update). *Blood Cells Mol Dis* 48: 53–61. doi: [10.1016/j.bcmd.2011.10.004](https://doi.org/10.1016/j.bcmd.2011.10.004) PMID: [22134107](https://pubmed.ncbi.nlm.nih.gov/22134107/)
144. Mathew EC, Shaw JM, Bonilla FA, Law SK, Wright DA (2000) A novel point mutation in CD18 causing the expression of dysfunctional CD11/CD18 leucocyte integrins in a patient with leucocyte adhesion deficiency (LAD). *Clin Exp Immunol* 121: 133–138. PMID: [10886250](https://pubmed.ncbi.nlm.nih.gov/10886250/)
145. Etzioni A, Frydman M, Pollack S, Avidor I, Phillips ML, et al. (1992) Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. *N Engl J Med* 327: 1789–1792. PMID: [1279426](https://pubmed.ncbi.nlm.nih.gov/1279426/)
146. Lühn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D (2001) The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. *Nat Genet* 28: 69–72. PMID: [11326279](https://pubmed.ncbi.nlm.nih.gov/11326279/)

147. Lubke T, Marquardt T, Etzioni A, Hartmann E, von Figura K, et al. (2001) Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. *Nat Genet* 28: 73–76. PMID: [11326280](#)
148. Helmus Y, Denecke J, Yakubenia S, Robinson P, Luhn K, et al. (2006) Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. *Blood* 107: 3959–3966. PMID: [16455955](#)
149. Etzioni A, Sturla L, Antonellis A, Green ED, Gershoni-Baruch R, et al. (2002) Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG) IIc founder effect and genotype/phenotype correlation. *Am J Med Genet* 110: 131–135. PMID: [12116250](#)
150. Kuijpers TW, Van Lier RA, Hamann D, de Boer M, Thung LY, et al. (1997) Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. *J Clin Invest* 100: 1725–1733. PMID: [9312170](#)
151. Kuijpers TW, van Bruggen R, Kamerbeek N, Tool AT, Hicsonmez G, et al. (2007) Natural history and early diagnosis of LAD-1/variant syndrome. *Blood* 109: 3529–3537. PMID: [17185466](#)
152. Kuijpers TW, van de Vijver E, Weterman MA, de Boer M, Tool AT, et al. (2009) LAD-1/variant syndrome is caused by mutations in FERMT3. *Blood* 113: 4740–4746. doi: [10.1182/blood-2008-10-182154](#) PMID: [19064721](#)
153. Harris ES, Smith TL, Springett GM, Weyrich AS, Zimmerman GA (2012) Leukocyte adhesion deficiency-I variant syndrome (LAD-Iv, LAD-III): molecular characterization of the defect in an index family. *Am J Hematol* 87: 311–313. doi: [10.1002/ajh.22253](#) PMID: [22139635](#)
154. van de Vijver E, De Cuyper IM, Gerrits AJ, Verhoeven AJ, Seeger K, et al. (2012) Defects in Glanzmann thrombasthenia and LAD-III (LAD-1v) syndrome: the role of integrin beta1 and beta3 in platelet adhesion to collagen. *Blood* 119: 583–586. doi: [10.1182/blood-2011-02-337188](#) PMID: [22065596](#)
155. Ambruso DR, Knall C, Abell AN, Panepinto J, Kurkchubasche A, et al. (2000) Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. *Proc Natl Acad Sci U S A* 97: 4654–4659. PMID: [10758162](#)
156. Accetta D, Syverson G, Bonacci B, Reddy S, Bengtson C, et al. (2011) Human phagocyte defect caused by a Rac2 mutation detected by means of neonatal screening for T-cell lymphopenia. *Journal of Allergy and Clinical Immunology* 127: 535–538.e532. doi: [10.1016/j.jaci.2010.10.013](#) PMID: [21167572](#)
157. Moutsopoulos NM, Konkel J, Sarmadi M, Eskan MA, Wild T, et al. (2014) Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. *Sci Transl Med* 6: 229ra240.
158. Gulino AV, Moratto D, Sozzani S, Cavadini P, Otero K, et al. (2004) Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. *Blood* 104: 444–452. PMID: [15026312](#)
159. Hayashi F, Means TK, Luster AD (2003) Toll-like receptors stimulate human neutrophil function. *Blood* 102: 2660–2669. PMID: [12829592](#)
160. Bouma G, Doffinger R, Patel SY, Peskett E, Sinclair JC, et al. (2009) Impaired neutrophil migration and phagocytosis in IRAK-4 deficiency. *Br J Haematol* 147: 153–156. doi: [10.1111/j.1365-2141.2009.07838.x](#) PMID: [19663824](#)
161. van Bruggen R, Drewniak A, Tool AT, Jansen M, van Houdt M, et al. (2010) Toll-like receptor responses in IRAK-4-deficient neutrophils. *J Innate Immun* 2: 280–287. doi: [10.1159/000268288](#) PMID: [20375545](#)
162. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, et al. (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. *Science* 299: 2076–2079. PMID: [12637671](#)
163. Enders A, Pannicke U, Berner R, Henneke P, Radlinger K, et al. (2004) Two siblings with lethal pneumococcal meningitis in a family with a mutation in Interleukin-1 receptor-associated kinase 4. *J Pediatr* 145: 698–700. PMID: [15520784](#)
164. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, et al. (2008) Pyogenic bacterial infections in humans with MyD88 deficiency. *Science* 321: 691–696. doi: [10.1126/science.1158298](#) PMID: [18669862](#)
165. Picard C, von Bernuth H, Ghandil P, Chrabieh M, Levy O, et al. (2010) Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. *Medicine (Baltimore)* 89: 403–425.
166. Picard C, Casanova JL, Puel A (2011) Infectious diseases in patients with IRAK-4, MyD88, NEMO, or I kappa B alpha deficiency. *Clin Microbiol Rev* 24: 490–497. doi: [10.1128/CMR.00001-11](#) PMID: [21734245](#)
167. Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, et al. (2009) A homozygous CARD9 mutation in a family with susceptibility to fungal infections. *N Engl J Med* 361: 1727–1735. doi: [10.1056/NEJMoa0810719](#) PMID: [19864672](#)

168. Drewniak A, Gazendam RP, Tool AT, van Houdt M, Jansen MH, et al. (2013) Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. *Blood* 121: 2385–2392. doi: [10.1182/blood-2012-08-450551](https://doi.org/10.1182/blood-2012-08-450551) PMID: [23335372](https://pubmed.ncbi.nlm.nih.gov/23335372/)
169. Gombart AF, Shiohara M, Kwok SH, Agematsu K, Komiyama A, et al. (2001) Neutrophil-specific granule deficiency: homozygous recessive inheritance of a frameshift mutation in the gene encoding transcription factor CCAAT/enhancer binding protein—epsilon. *Blood* 97: 2561–2567. PMID: [11313242](https://pubmed.ncbi.nlm.nih.gov/11313242/)
170. Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM (2013) Myeloperoxidase: a front-line defender against phagocytosed microorganisms. *J Leukoc Biol* 93: 185–198. doi: [10.1189/jlb.0712349](https://doi.org/10.1189/jlb.0712349) PMID: [23066164](https://pubmed.ncbi.nlm.nih.gov/23066164/)
171. Moraes TJ, Zurawska JH, Downey GP (2006) Neutrophil granule contents in the pathogenesis of lung injury. *Curr Opin Hematol* 13: 21–27. PMID: [16319683](https://pubmed.ncbi.nlm.nih.gov/16319683/)
172. Grommes J, Soehnlein O (2011) Contribution of neutrophils to acute lung injury. *Mol Med* 17: 293–307. doi: [10.2119/molmed.2010.00138](https://doi.org/10.2119/molmed.2010.00138) PMID: [21046059](https://pubmed.ncbi.nlm.nih.gov/21046059/)
173. Kolaczowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. *Nat Rev Immunol* 13: 159–175. doi: [10.1038/nri3399](https://doi.org/10.1038/nri3399) PMID: [23435331](https://pubmed.ncbi.nlm.nih.gov/23435331/)
174. Williams AE, Chambers RC (2014) The mercurial nature of neutrophils: still an enigma in ARDS? *Am J Physiol Lung Cell Mol Physiol* 306: L217–230. doi: [10.1152/ajplung.00311.2013](https://doi.org/10.1152/ajplung.00311.2013) PMID: [24318116](https://pubmed.ncbi.nlm.nih.gov/24318116/)
175. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, et al. (2010) Intravascular danger signals guide neutrophils to sites of sterile inflammation. *Science* 330: 362–366. doi: [10.1126/science.1195491](https://doi.org/10.1126/science.1195491) PMID: [20947763](https://pubmed.ncbi.nlm.nih.gov/20947763/)
176. Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. *Nature* 510: 92–101. doi: [10.1038/nature13479](https://doi.org/10.1038/nature13479) PMID: [24899309](https://pubmed.ncbi.nlm.nih.gov/24899309/)
177. Condliffe AM, Kitchen E, Chilvers ER (1998) Neutrophil priming: pathophysiological consequences and underlying mechanisms. *Clin Sci (Lond)* 94: 461–471. PMID: [9682667](https://pubmed.ncbi.nlm.nih.gov/9682667/)
178. Summers C, Chilvers ER, Peters AM (2014) Mathematical modeling supports the presence of neutrophil depriming in vivo. *Physiol Rep* 2: e00241. doi: [10.1002/phy2.241](https://doi.org/10.1002/phy2.241) PMID: [24760504](https://pubmed.ncbi.nlm.nih.gov/24760504/)
179. Singh A, Zarembek KA, Kuhns DB, Gallin JI (2009) Impaired priming and activation of the neutrophil NADPH oxidase in patients with IRAK4 or NEMO deficiency. *J Immunol* 182: 6410–6417. doi: [10.4049/jimmunol.0802512](https://doi.org/10.4049/jimmunol.0802512) PMID: [19414794](https://pubmed.ncbi.nlm.nih.gov/19414794/)
180. McMillan SJ, Sharma RS, McKenzie EJ, Richards HE, Zhang J, et al. (2013) Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b beta2-integrin-dependent signaling. *Blood* 121: 2084–2094. doi: [10.1182/blood-2012-08-449983](https://doi.org/10.1182/blood-2012-08-449983) PMID: [23315163](https://pubmed.ncbi.nlm.nih.gov/23315163/)
181. Davidson BA, Vethanayagam RR, Grimm MJ, Mullan BA, Raghavendran K, et al. (2013) NADPH oxidase and Nrf2 regulate gastric aspiration-induced inflammation and acute lung injury. *J Immunol* 190: 1714–1724. doi: [10.4049/jimmunol.1202410](https://doi.org/10.4049/jimmunol.1202410) PMID: [23296708](https://pubmed.ncbi.nlm.nih.gov/23296708/)
182. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, et al. (2012) The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. *Nat Med* 18: 1217–1223. doi: [10.1038/nm.2843](https://doi.org/10.1038/nm.2843) PMID: [22820644](https://pubmed.ncbi.nlm.nih.gov/22820644/)
183. Achouiti A, Vogl T, Urban CF, Rohm M, Hommes TJ, et al. (2012) Myeloid-related protein-14 contributes to protective immunity in gram-negative pneumonia derived sepsis. *PLoS Pathog* 8: e1002987. doi: [10.1371/journal.ppat.1002987](https://doi.org/10.1371/journal.ppat.1002987) PMID: [23133376](https://pubmed.ncbi.nlm.nih.gov/23133376/)
184. Weckbach LT, Gola A, Winkelmann M, Jakob SM, Groesser L, et al. (2014) The cytokine midkine supports neutrophil trafficking during acute inflammation by promoting adhesion via beta2 integrins (CD11/CD18). *Blood* 123: 1887–1896. doi: [10.1182/blood-2013-06-510875](https://doi.org/10.1182/blood-2013-06-510875) PMID: [24458438](https://pubmed.ncbi.nlm.nih.gov/24458438/)
185. Jakob SM, Pick R, Brechtefeld D, Nussbaum C, Kiefer F, et al. (2013) Hematopoietic progenitor kinase 1 (HPK1) is required for LFA-1-mediated neutrophil recruitment during the acute inflammatory response. *Blood* 121: 4184–4194. doi: [10.1182/blood-2012-08-451385](https://doi.org/10.1182/blood-2012-08-451385) PMID: [23460610](https://pubmed.ncbi.nlm.nih.gov/23460610/)
186. Sutherland TE, Logan N, Ruckerl D, Humbles AA, Allan SM, et al. (2014) Chitinase-like proteins promote IL-17-mediated neutrophilia in a tradeoff between nematode killing and host damage. *Nat Immunol*.
187. Christoffersson G, Vagesjo E, Vandooren J, Liden M, Massena S, et al. (2012) VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. *Blood* 120: 4653–4662. doi: [10.1182/blood-2012-04-421040](https://doi.org/10.1182/blood-2012-04-421040) PMID: [22966168](https://pubmed.ncbi.nlm.nih.gov/22966168/)
188. Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, et al. (2006) A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. *Nat Med* 12: 317–323. PMID: [16474398](https://pubmed.ncbi.nlm.nih.gov/16474398/)
189. Snelgrove RJ, Jackson PL, Hardison MT, Noerager BD, Kinloch A, et al. (2010) A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. *Science* 330: 90–94. doi: [10.1126/science.1190594](https://doi.org/10.1126/science.1190594) PMID: [20813919](https://pubmed.ncbi.nlm.nih.gov/20813919/)

190. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature* 418: 191–195. PMID: [12110890](#)
191. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, et al. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. *J Exp Med* 209: 551–563. doi: [10.1084/jem.20111739](#) PMID: [22370717](#)
192. Brandau S, Dumitru CA, Lang S (2013) Protumor and antitumor functions of neutrophil granulocytes. *Semin Immunopathol* 35: 163–176. doi: [10.1007/s00281-012-0344-6](#) PMID: [23007469](#)
193. Bauer S, Abdgawad M, Gunnarsson L, Segelmark M, Tapper H, et al. (2007) Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. *J Leukoc Biol* 81: 458–464. PMID: [17077162](#)
194. Hartl D, Krauss-Etschmann S, Koller B, Hordijk PL, Kuijpers TW, et al. (2008) Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. *J Immunol* 181: 8053–8067. PMID: [19017998](#)
195. Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, et al. (2008) Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. *Proc Natl Acad Sci U S A* 105: 4335–4339. doi: [10.1073/pnas.0712386105](#) PMID: [18334635](#)
196. Sigua JA, Buelow B, Cheung DS, Buell E, Hunter D, et al. (2014) CD49d-expressing neutrophils differentiate atopic from nonatopic individuals. *J Allergy Clin Immunol* 133: 901–904 e905. doi: [10.1016/j.jaci.2013.09.035](#) PMID: [24360325](#)
197. Puellmann K, Kaminski WE, Vogel M, Nebe CT, Schroeder J, et al. (2006) A variable immunoreceptor in a subpopulation of human neutrophils. *Proc Natl Acad Sci U S A* 103: 14441–14446. PMID: [16983085](#)
198. Beyrau M, Bodkin JV, Nourshargh S (2012) Neutrophil heterogeneity in health and disease: a revitalized avenue in inflammation and immunity. *Open Biol* 2: 120134. doi: [10.1098/rsob.120134](#) PMID: [23226600](#)
199. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. *Cancer Cell* 16: 183–194. doi: [10.1016/j.ccr.2009.06.017](#) PMID: [19732719](#)
200. Tsuda Y, Takahashi H, Kobayashi M, Hanafusa T, Herndon DN, et al. (2004) Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant *Staphylococcus aureus*. *Immunity* 21: 215–226. PMID: [15308102](#)
201. Matsushima H, Geng S, Lu R, Okamoto T, Yao Y, et al. (2013) Neutrophil differentiation into a unique hybrid population exhibiting dual phenotype and functionality of neutrophils and dendritic cells. *Blood* 121: 1677–1689. doi: [10.1182/blood-2012-07-445189](#) PMID: [23305731](#)
202. Geng S, Matsushima H, Okamoto T, Yao Y, Lu R, et al. (2013) Emergence, origin, and function of neutrophil-dendritic cell hybrids in experimentally induced inflammatory lesions in mice. *Blood* 121: 1690–1700. doi: [10.1182/blood-2012-07-445197](#) PMID: [23305733](#)
203. Iking-Konert C, Ostendorf B, Sander O, Jost M, Wagner C, et al. (2005) Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. *Annals of the Rheumatic Diseases* 64: 1436–1442. PMID: [15778239](#)
204. Radsak M, Iking-Konert C, Stegmaier S, Andrassy K, Hänsch GM (2000) Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. *Immunology* 101: 521–530. PMID: [11122456](#)
205. Pliyev BK, Sumarokov AB, Buriachkovskaia LI, Menshikov M (2011) Extracellular acidosis promotes neutrophil transdifferentiation to MHC class II-expressing cells. *Cell Immunol* 271: 214–218. doi: [10.1016/j.cellimm.2011.08.020](#) PMID: [21924707](#)
206. Dyugovskaya L, Berger S, Polyakov A, Lavie L (2014) The development of giant phagocytes in long-term neutrophil cultures. *J Leukoc Biol* 96: 511–521. doi: [10.1189/jlb.0813437](#) PMID: [24577569](#)
207. Köffel R, Meshcheryakova A, Warszawska J, Hennig A, Wagner K, et al. (2014) Monocytic cell differentiation from band-stage neutrophils under inflammatory conditions via MKK6 activation. *Blood* 124: 2713–2724. doi: [10.1182/blood-2014-07-588178](#) PMID: [25214442](#)
208. Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, et al. (2009) Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. *Proc Natl Acad Sci U S A* 106: 5779–5783. doi: [10.1073/pnas.0813410106](#) PMID: [19293384](#)
209. Laval J, Touhami J, Herzenberg LA, Conrad C, Taylor N, et al. (2013) Metabolic adaptation of neutrophils in cystic fibrosis airways involves distinct shifts in nutrient transporter expression. *J Immunol* 190: 6043–6050. doi: [10.4049/jimmunol.1201755](#) PMID: [23690474](#)

210. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, et al. (2013) Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. *Nat Immunol* 14: 211–220. doi: [10.1038/ni.2526](https://doi.org/10.1038/ni.2526) PMID: [23354483](https://pubmed.ncbi.nlm.nih.gov/23354483/)
211. Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, et al. (2013) Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. *J Cyst Fibros* 12: 241–248. doi: [10.1016/j.jcf.2012.08.016](https://doi.org/10.1016/j.jcf.2012.08.016) PMID: [22995323](https://pubmed.ncbi.nlm.nih.gov/22995323/)